These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 15462322)

  • 1. [Dynamics of markers of blood inflammation against the background of antibacterial therapy in children with mucoviscidosis, with the various regimens of intake of pancreatic enzymes].
    Kashirskaia NIu; Shmarina GV; Kapranov NI; Pukhal'skiĭ AL
    Eksp Klin Gastroenterol; 2004; (2):48-52, 109. PubMed ID: 15462322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety of cefoperazone/sulbactam in the treatment of children with mucoviscidosis during exacerbation of the bronchopulmonary process].
    Semykin SIu; Postnikov SS; Polikarpova SV; Perederko LV
    Antibiot Khimioter; 2003; 48(12):18-21. PubMed ID: 15176099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Production of elastase, exotoxin A and alkaline protease during bronchopulmonary exacerbations in patients with mucoviscidosis chronically infected by Pseudomonas aeruginosa].
    Jaffar-Bandjee MC; Carrere J; Bally M; Chazalette JP; Galabert C
    Pathol Biol (Paris); 1994 May; 42(5):505-9. PubMed ID: 7824322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
    Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
    Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A more objective approach to the evaluation of antimicrobial therapy in cystic fibrosis.
    Valletta EA; Rigo A; Bonazzi L; Zanolla L; Mastella G
    Acta Univ Carol Med (Praha); 1990; 36(1-4):44-5. PubMed ID: 2130717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tobramycin and carbenicillin compared with gentamicin and carbenicillin in the treatment of infection with Pseudomonas aeruginosa in adult patients with cystic fibrosis.
    Hodson ME; Wingfield HJ; Batten JC
    Br J Dis Chest; 1983 Jan; 77(1):71-7. PubMed ID: 6407508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TOBI Podhaler for cystic fibrosis patients with Pseudomonas aeruginosa.
    Farinde A
    Nurse Pract; 2015 Jul; 40(7):16-7. PubMed ID: 26080292
    [No Abstract]   [Full Text] [Related]  

  • 8. [Detection and management of early Pseudomonas aeruginosa infection in patients with cystic fibrosis].
    Kernen Y; Sauty A; Roulet M
    Rev Med Suisse; 2005 Mar; 1(9):637-8, 640. PubMed ID: 15813341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Azlocillin treatment of Pseudomonas aeruginosa bronchopulmonary infections in children with cystic fibrosis].
    Grenier B; Gilly R
    Presse Med; 1984 Mar; 13(13):815-8. PubMed ID: 6231602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Problems of antibiotic therapy in mucoviscidosis].
    Steinitz H
    Z Allgemeinmed; 1972 Aug; 48(24):1085-9. PubMed ID: 4649651
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevalence of resistant Pseudomonas aeruginosa with elective and rescue intravenous antibiotic regimens in children with cystic fibrosis.
    Smyth E; David TJ; Patel L; Ashcroft P; Sanyal D; Vyas J
    Int J Antimicrob Agents; 2005 Jul; 26(1):95-6. PubMed ID: 15970432
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pseudomonas aeruginosa and mucoviscidosis].
    Lenoir G
    Rev Pneumol Clin; 1995; 51(3):151-9. PubMed ID: 7569577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.
    Emiralioglu N; Yalcin E; Meral A; Sener B; Dogru D; Ozcelik U; Kiper N
    J Clin Pharm Ther; 2016 Aug; 41(4):419-23. PubMed ID: 27311742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic treatment of cystic fibrosis.
    Jedlicková Z; Vávrová V; Houstĕk J; Výmola F
    Acta Univ Carol Med (Praha); 1990; 36(1-4):42-3. PubMed ID: 2130716
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
    Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased plasma fatty acid concentrations after respiratory exacerbations are associated with elevated oxidative stress in cystic fibrosis patients.
    Wood LG; Fitzgerald DA; Gibson PG; Cooper DM; Garg ML
    Am J Clin Nutr; 2002 Apr; 75(4):668-75. PubMed ID: 11916752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.
    Ang JY; Abdel-Haq N; Zhu F; Thabit AK; Nicolau DP; Satlin MJ; van Duin D
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5627-30. PubMed ID: 27664282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM; Waugh J; Noble S
    Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaches to the treatment of initial Pseudomonas aeruginosa infection in children who have cystic fibrosis.
    Lahiri T
    Clin Chest Med; 2007 Jun; 28(2):307-18. PubMed ID: 17467550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.